Researchers ID biomarkers for early transplant rejection; Study questions use of EFGR for lung cancer prognosis;

> A team of investigators at Boston Children's Hospital and Beth Israel Deaconess Medical Center say they have nailed down a set of biomarkers that can be used to identify the early signs of heart transplant rejection. The work provides physicians a chance to determine if a heart is being rejected before it fails. Report

> A new study indicates that testing for the EGFR biomarker is not a good way to evaluate the likely course of lung cancer.  The conclusion: "Although the EGFR mutation is a predictive marker for EGFR TKI response, the presence of EGFR mutation is not a prognostic factor." Story

> Selventa says it is developing a new class of diagnostic test that can consist of "multi-omic" biomarkers to guide physicians' choice of therapies. Release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.